<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601819</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2018.048</org_study_id>
    <secondary_id>HUM00144759</secondary_id>
    <nct_id>NCT03601819</nct_id>
  </id_info>
  <brief_title>Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders</brief_title>
  <official_title>Phase Ib, Open Label, Single Center Study of Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will determine the safety and tolerability of Pacritinib in patients with
      relapsed/refractory lymphoproliferative disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities (DLT)</measure>
    <time_frame>At 28 days</time_frame>
    <description>Dose limiting toxicity (DLT) rate during the 1st cycle (28 days) of pacritinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients that respond to treatment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall response rate (ORR), defined as best disease response recorded from first day of treatment until disease progression or initiation of new antineoplastic therapy.
Responses for patients with NHL or small lymphocytic lymphoma will be performed in accordance with the Revised Lugano classification staging system for non-Hodgkin's Lymphoma. Responses for patients with CLL will be evaluated in accordance with criteria of the International Workshop on Chronic Lymphocytic Leukemia, with the exception that lymphocytosis will not be the sole criteria for disease progression. Responses for CTCL will be assessed by the modified Severity Weighted Assessment Tool, response in blood, nodes, viscera, and the global composite scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients that experience a complete response (CR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Responses for patients with NHL or small lymphocytic lymphoma will be performed in accordance with the Revised Lugano classification staging system for non-Hodgkin's Lymphoma. Responses for patients with CLL will be evaluated in accordance with criteria of the International Workshop on Chronic Lymphocytic Leukemia, with the exception that lymphocytosis will not be the sole criteria for disease progression. Responses for CTCL will be assessed by the modified Severity Weighted Assessment Tool, response in blood, nodes, viscera, and the global composite scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR, defined as time from documented remission to the time of death, relapse, or initiation of alternative antineoplastic.
Responses for patients with NHL or small lymphocytic lymphoma will be performed in accordance with the Revised Lugano classification staging system for non-Hodgkin's Lymphoma. Responses for patients with CLL will be evaluated in accordance with criteria of the International Workshop on Chronic Lymphocytic Leukemia, with the exception that lymphocytosis will not be the sole criteria for disease progression. Responses for CTCL will be assessed by the modified Severity Weighted Assessment Tool, response in blood, nodes, viscera, and the global composite scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to next treatment, defined as time from first dose of pacritinib to initiation of alternative antineoplastic therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Lymphoma, T-Cell, Peripheral</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Pacritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg twice daily (with possible dose reduction to 100 mg twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.</description>
    <arm_group_label>Pacritinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of any of the following:

               1. Relapsed/refractory cutaneous (stage IIb-IV by ISCL/EORTC staging criteria) or
                  peripheral T-cell lymphoma with progression after the last line of therapy and
                  refractory to/intolerant of or have a contraindication to all established
                  therapies known to provide clinical benefit (including brentuximab vedotin for
                  patients with anaplastic large cell lymphomas) OR

               2. Chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL),
                  Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) or mantle
                  cell lymphoma (MCL) with disease progression on ibrutinib or who discontinue
                  ibrutinib due to toxicity/intolerance. In addition, patients should be refractory
                  to/intolerant of or have a contraindication to all established therapies known to
                  provide clinical benefit OR

               3. Any lymphoproliferative disorder who have failed at least 2 prior therapies and
                  are refractory to/intolerant of or have a contraindication to all established
                  therapies known to provide clinical benefit and have had mutational analysis or
                  sequencing studies performed in a CLIA certified laboratory demonstrating a
                  mutation or gene fusion involving MyD88, JAK2, JAK3, TYK2, or IRAK1 that are
                  known or suspected to be &quot;activating&quot; (gain-of-function).

          -  Age ≥ 18 at time of enrollment

          -  ECOG ≤ 2 (Eastern Cooperative Oncology Group scoring system used to quantify general
             well-being and activities of daily life; scores range from 0 to 5 where 0 represents
             perfect health and 5 represents death.)

          -  Adequate organ and marrow function as defined in the protocol

          -  Ability to take oral medication without crushing, dissolving or chewing tablets.

          -  In the investigator's opinion, the patient requires immediate treatment.

          -  Ability to understand and the willingness to sign a written informed consent.

          -  In the investigator's opinion, the patient has the ability to communicate
             satisfactorily with the investigator and the study team, to participate fully in the
             study, and comply with all requirements.

        Exclusion Criteria:

          -  History of, or a concurrent, clinically significant illness, medical condition or
             laboratory abnormality that, in the investigator's opinion, could affect the conduct
             of the study

          -  Pregnant or breast feeding women

          -  Unwilling or unable to use a medically acceptable form of contraception during the
             time of participation in the trial (sexual abstinence is permissible) unless
             documented successful vasectomy, hysterectomy, bilateral oophorectomy or
             post-menopausal for at least 2 years

          -  Uncontrolled current illness, including, but not limited to the following: Ongoing or
             active infections requiring intravenous antimicrobials; symptomatic congestive heart
             failure defined as NYHA class II, III or IV (Appendix II); unstable angina pectoris
             within 6 months of study enrollment; unstable cardiac arrhythmia; history of
             myocardial infarction, stroke or intracranial hemorrhage within 6 months prior to
             enrollment; moderate to severe hepatic impairment (Child-Pugh class B or C);
             psychiatric illness or social situations that would limit compliance with study
             requirements

          -  Known HIV infection

          -  Known positive Hepatitis B surface antigen or Hep C virus

          -  Recent (within 21 days of initiation of therapy, day 1) major surgery

          -  Less than 14 days have elapsed since last radiation therapy or chemotherapy treatment
             or patient has not recovered from all clinically significant treatment-related
             toxicity; less than 90 days have passed since date of autologous stem cell transplant
             and patient has not recovered to ≤grade 1 toxicity related to this procedure

          -  Use of systemic steroids (oral, inhaled, nasal, topical) at a dose less &gt; 10 mg/day of
             prednisone

          -  Prior treatment with pacritinib

          -  Uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP).
             Coombs positivity in absence of hemolysis is not an exclusion.

          -  Requires anticoagulation with heparin, warfarin or equivalent Vit K antagonist

          -  History of significant bleeding (≥Grade 2 by CTCAE) history or complications
             (including bleeding that may have occurred while on ibrutinib)

          -  Hypersensitivity or allergic reaction to compounds related to pacritinib

          -  Treatment with potent CYP450 inducers and strong CYP3A4 inhibitors for which no
             alternative is available; treatment with strong CYP450 inducers or strong CYP3A4
             inhibitors within 2 weeks of initiation of therapy, day 1

          -  Concurrent administration of QTc prolonging agents; significant QTc prolonging agents
             must be stopped within 5 half-lives of day 1.

          -  Any gastrointestinal or metabolic condition that could interfere with the absorption
             of oral medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Wilcox, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Wilcox, MD, PhD</last_name>
    <phone>734-615-9799</phone>
    <email>rywilcox@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Wilcox, MD, PhD</last_name>
      <phone>734-615-9799</phone>
      <email>rywilcox@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Wilcox, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>MyD88</keyword>
  <keyword>JAK2</keyword>
  <keyword>JAK3</keyword>
  <keyword>TYK2</keyword>
  <keyword>IRAK1</keyword>
  <keyword>CLL</keyword>
  <keyword>SMZL</keyword>
  <keyword>LPL</keyword>
  <keyword>WM</keyword>
  <keyword>MCL</keyword>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

